Pharmacopsychiatry
January 19, 2022
Hitoshi Sakurai, Kengo Yonezawa, Hideaki Tani et al.
35 citations
Abstract Introduction There is an imminent need for faster-acting and more effective antidepressants beyond the monoaminergic hypothesis. Methods We systematically searched the US Clinical Trials registry for antidepressant compounds with completed phase II and III trials. Compounds that demonstrated significant superiority over placebo in the primary outcome measure in the latest phase of...
Frontiers in Psychiatry
January 3, 2022
Richard Matzopoulos, Robert Morlock, Amy Morlock et al.
43 citations
Introduction: Popular media coverage of psychedelics use, growing research into this class of compounds for psychiatry and decriminalization initiatives, are transforming the public perception of psychedelics. However, little is known about levels of knowledge and psychedelic mushroom (PM) use among American adults. Methods: We examined PM use and various measures of health status, quality of...
Psychiatric News
2022
T. D'Arrigo
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Clozapine REMS; Aduhelm; BNC210 Fast Tracked for Social Anxiety Disorder; and MoreTerri D'ArrigoTerri D'ArrigoPublished Online:29 Dec 2021https://doi.org/10.1176/appi.pn.2022.1.2Aduhelm Shows Promise for Alzheimer's DiseaseTwo phase 3 clinical trials of Aduhelm (aducanumab) showed a correlation between plasma...
Frontiers in Psychiatry
2022
Charles L. Raison, Rakesh Jain, Andrew Penn et al.
75 citations
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A...
2022
Nicole Amavisca, Nicole Amavisca
1 citation
Given the number of people who are treated for depression each year and the knowledge that treatments work differently for everyone, there is a pressing need to provide a variety of treatment options. Although psychedelic research had been halted for a few decades due to recreational abuse, there has been revived interest due to its therapeutic potential in the treatment of mood disorders and...
Journal of Psychopharmacology
December 17, 2021
Josephine Marschall, George Fejer, Pascal Lempe et al.
69 citations
Background: Microdoses of psychedelics (i.e. a sub-hallucinogenic dose taken every third day) can reduce symptoms of depression, anxiety and stress according to anecdotal reports and observational studies. Research with medium to high doses of psilocybin points towards potential underlying mechanisms, including the modulation of emotion and interoceptive processing. Aims: In this preregistered...
Scientific Reports
November 18, 2021
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey et al.
78 citations
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers ( n = 4050) and non-microdosers ( n = 4653) via a mobile application. Psilocybin was the most commonly...
Current Opinion in Psychiatry
November 15, 2021
Jerome Sarris, Diego Pinzon Rubiano, Kimberley Day et al.
12 citations
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent findings Serotonergic psychedelics have been found to modulate brain networks underlying various...
Psychiatry Investigation
October 10, 2021
Chia‐ling Yu, Fu-Chi Yang, Szu‐nian Yang et al.
57 citations
Objective To systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms.Methods The Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model.Results Overall,...
European Psychologist
September 17, 2021
Matthias Forstmann, Christina Sagioglou
6 citations
Abstract. After decades of stagnation, research on psychedelic substances (such as lysergic acid diethylamide [LSD], psilocybin, or N,N-dimethyltryptamine [DMT]) has experienced a renaissance over the last 10 years, with various major research programs being conducted across Europe and the United States. This research primarily investigates the potential of psychedelics in the treatment of...